Corlanor
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Corlanor (ivabradine; Servier/Amgen/Ono Pharmaceutical) blocks f-channels and inhibits the f-current, a modulator of the heart’s pacemaker activity. Heart rate (HR) depends on the speed of diastolic depolarization of myocytes from the sinus node. By binding to the f-channels of sinoatrial cells, Corlanor blocks the inward flow of sodium and potassium. This prolongs the myocytes’ depolarization phase, and slows HR. A lower HR decreases cardiac oxygen consumption, and prolonged diastolic times increase myocardial perfusion. Corlanor’s improvements in overall oxygen levels help to reduce cardiovascular risk. The drug’s pure HR-lowering properties prevent it from affecting contractility, or intracardiac conduction.
TABLE OF CONTENTS
4 Product Profiles
4 Corlanor : Chronic heart failure (CHF)
LIST OF FIGURES
8 Figure 1: Corlanor for chronic heart failure – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Corlanor for chronic heart failure
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Corlanor for chronic heart failure
12 Figure 4: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: Corlanor drug profile
6 Table 2: Corlanor pivotal phase III trial data in chronic heart failure
7 Table 3: Corlanor Phase II trial data in chronic heart failure
13 Table 4: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
European Surgical Procedure Volumes: Breast, general, gynecologic, organ transplant,... 
Sign up to the